The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedKohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Self-citationMolecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Self-citationKwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,354
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citationLynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Self-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
Self-citationRibas, A., Kefford, R., Marshall, M. A., Punt, C. J. A., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 805
Self-citationShuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.47 · Cited by 804
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Self-citationThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Self-citationDuraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
Sánchez-Fueyo, A., Tian, J., Picarella, D., Domenig, C., Zheng, X. X., Sabatos, C. A., Manlongat, N., Bender, O., Kamradt, T., Kuchroo, V. K., et al. (2003) · Nature Immunology · doi:10.1038/ni987 · Cited by 712
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
CD40/CD154 Interactions at the Interface of Tolerance and Immunity
Quezada, S. A., Jarvinen, L. Z., Lind, E. F., & Noelle, R. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104533 · Cited by 683
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Self-citationHino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & Tokura, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 667
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Self-citationReck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
Wang, C., Thudium, K. B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 601
Self-citationBevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., Patterson, J. W., & Slingluff, C. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3218 · Cited by 590
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., Wollner, I., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 545
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Self-citationKouo, T., Huang, L., Pucsek, A. B., Cao, M., Solt, S., Armstrong, T., & Jaffee, E. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0150 · Cited by 531
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 528
Immune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515
Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, B. D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., Walker, J., Gonzalez, I., Meeuwsen, T., Fox, B. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4174 · Cited by 496
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M. T., Town, L., Ritchie, D. S., Colonna, M., Andrews, D. M., & Smyth, M. J. (2014) · Nature Immunology · doi:10.1038/ni.2850 · Cited by 492
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2063 · Cited by 488
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050940 · Cited by 466
Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., & Sakaguchi, S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.200509402092c · Cited by 462
Weber, J. S., Dummer, R., de Pril, V., Lebbé, C., Hodi, F. S., & for the MDX010‐20 Investigators (2013) · Cancer · doi:10.1002/cncr.27969 · Cited by 447
Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0985 · Cited by 435
Self-citationAgonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 407
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Lu, Y.-C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401
Grimaldi, A. M., Simeone, E., Giannarelli, D., Muto, P., Falivene, S., Borzillo, V., Giugliano, F. M., Sandomenico, F., Petrillo, A., Curvietto, M., et al. (2014) · OncoImmunology · doi:10.4161/onci.28780 · Cited by 379
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response
Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., Welters, M. J. P., van der Burg, S., Kapiteijn, E., Michielin, O., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008918 · Cited by 378
Self-citationHendriks, J., Xiao, Y., & Borst, J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030916 · Cited by 376
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Wang, C., Lin, G. H. Y., McPherson, A. J., & Watts, T. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00765.x · Cited by 298
Natural killer cell recognition of missing self
Kärre, K. (2008) · Nature Immunology · doi:10.1038/ni0508-477 · Cited by 296
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control
Fridman, W. H., Galon, J., Dieu-Nosjean, M.-C., Cremer, I., Fisson, S., Damotte, D., Pagès, F., Tartour, E., & Sautès-Fridman, C. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_46 · Cited by 258
Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J. S., Galbraith, S. M., Targan, S. R., & Wang, H. L. (2010) · PubMed · Cited by 258
Self-citationEngagement of CD27 with its ligand CD70 provides a second signal for T cell activation.
Hintzen, R. Q., Lens, S. M. A., Lammers, K., Kuiper, H., Beckmann, M. P., & van Lier, R. A. W. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.6.2612 · Cited by 243
Jenkins, M. K., Chu, H. H., McLachlan, J. B., & Moon, J. J. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101253 · Cited by 236
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al-Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 226
Kwon, E. D., Foster, B. A., Hurwitz, A. A., Madias, C., Allison, J. P., Greenberg, N. M., & Burg, M. B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15074 · Cited by 222
Mitigating the toxic effects of anticancer immunotherapy
Gangadhar, T. C., & Vonderheide, R. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.245 · Cited by 222
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Marabelle, A., Kohrt, H., Caux, C., & Levy, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2116 · Cited by 214
Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Tim-3, a negative regulator of anti-tumor immunity
Anderson, A. C. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.005 · Cited by 204
Role of CD27/CD70 pathway of activation in immunity and tolerance
Denoeud, J., & Moser, M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0610351 · Cited by 197
Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
Bullock, T. N. J., & Yagita, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.710 · Cited by 182
Immunotherapy of Cancer with 4-1BB
Vinay, D. S., & Kwon, B. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0677 · Cited by 180
Houot, R., & Levy, R. (2009) · Blood · doi:10.1182/blood-2008-07-170274 · Cited by 178
Kocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
Characterization of the human CD27 ligand, a novel member of the TNF gene family.
Hintzen, R. Q., Lens, S. M., Beckmann, M. P., Goodwin, R. G., Lynch, D., & van Lier, R. A. W. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.4.1762 · Cited by 175
Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174
White, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Ménard, C., Martin, F., Apetoh, L., Bouyer, F., & Ghiringhelli, F. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0505-6 · Cited by 167
Fisher, T. S., Kamperschroer, C., Oliphant, T., Love, V. A., Lira, P. D., Doyonnas, R., Bergqvist, S., Baxi, S. M., Rohner, A., Shen, A. C., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1237-1 · Cited by 166
Science gone translational: the OX40 agonist story
Weinberg, A. D., Morris, N. P., Kovacsovics-Bankowski, M., Urba, W. J., & Curti, B. D. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01069.x · Cited by 161
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Sznol, M., Kluger, H. M., Callahan, M. K., Postow, M. A., Gordon, R. A., Segal, N. H., Rizvi, N. A., Lesokhin, A. M., Atkins, M. B., Kirkwood, J. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba9003 · Cited by 151
Modulation of GITR for cancer immunotherapy
Schaer, D., Murphy, J. T., & Wolchok, J. D. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.011 · Cited by 147
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Flies, D. B., Sandler, B. J., Sznol, M., & Chen, L. (2011) · PubMed Central · Cited by 143
Comín-Anduix, B., Chodon, T., Sazegar, H., Matsunaga, D. R., Mock, S., Jalil, J., Escuin-Ordinas, H., Chmielowski, B., Koya, R. C., & Ribas, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1911 · Cited by 143
Ascierto, P. A., Kalos, M. D., Schaer, D., Callahan, M. K., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2982 · Cited by 141
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hammers, H. J., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Razak, A. R. A., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.4504 · Cited by 141
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 138
Self-citationRibas, A., Comín-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 135
The CD4-like molecule LAG-3, biology and therapeutic applications
Sierro, S. R., Romero, P. J., & Speiser, D. E. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712598.2011.540563 · Cited by 133
Antonia, S. J., Gettinger, S. N., Chow, L. Q. M., Juergens, R. A., Borghaei, H., Shen, Y., Harbison, C. T., Chen, A. C., Ready, N., & Rizvi, N. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8023 · Cited by 125
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Weigelin, B., Bolaños, E., Teijeira, Á., Martínez‐Forero, I., Labiano, S., Azpilikueta, A., Morales‐Kastresana, A., Quetglas, J. I., Wagena, E., Sánchez-Paulete, A. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506357112 · Cited by 118
Self-citationLi, F., & Ravetch, J. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319502110 · Cited by 115
Zhou, P., L’Italien, L., Hodges, D., & Schebye, X. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7365 · Cited by 109
CD94/NKG2A Inhibits NK Cell Activation by Disrupting the Actin Network at the Immunological Synapse
Masilamani, M., Nguyen, C. M.-C., Kabát, J., Borrego, F., & Coligan, J. E. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3590 · Cited by 106
Morales‐Kastresana, A., Sanmamed, M. F., Rodríguez, I., Palazón, A., Martínez‐Forero, I., Labiano, S., Hervás‐Stubbs, S., Sangro, B., Ochoa, C., Rouzaut, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1189 · Cited by 105
Self-citationRuby, C. E., Redmond, W. L., Haley, D. P., & Weinberg, A. D. (2006) · European Journal of Immunology · doi:10.1002/eji.200636428 · Cited by 98
Vemurafenib Sensitivity Skin Reaction after Ipilimumab
Harding, J. J., Pulitzer, M. P., & Chapman, P. B. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1114329 · Cited by 94
Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 91
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita∥, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 89
Characterization of murine CD70, the ligand of the TNF receptor family member CD27
Tesselaar, K., Gravestein, L. A., van Schijndel, G. M. W., Borst, J. G., & van Lier, R. A. W. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4959 · Cited by 83
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Moschella, F., Proietti, E., Capone, I., & Belardelli, F. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05464.x · Cited by 76
CD27/CD70 interaction directly induces natural killer cell killing activity
Yang, F., Agematsu, K., NAKAZAWA, T., Mori, T., Ito, S., Kobata, T., Morimoto, C., & Komiyama, A. (1996) · Immunology · doi:10.1111/j.1365-2567.1996.tb00017.x · Cited by 74
Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma Model
Newcomb, E. W., Lukyanov, Y., Kawashima, N., Alonso‐Basanta, M., Wang, S., Liu, M., Jure‐Kunkel, M., Zagzag, D., Demaria, S., & Formenti, S. C. (2010) · Radiation Research · doi:10.1667/rr1904.1 · Cited by 68
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
Houot, R., Kohrt, H. E. K., Marabelle, A., & Levy, R. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.07.003 · Cited by 67
KIR and KIR ligand polymorphism: a new area for clinical applications?
Falco, M., Moretta, L., Moretta, A., & Bottino, C. (2013) · Tissue Antigens · doi:10.1111/tan.12262 · Cited by 61
Requirement for CD70 in CD4+ Th Cell-Dependent and Innate Receptor-Mediated CD8+ T Cell Priming
Taraban, V. Y., Rowley, T. F., Tough, D. F., & Al‐Shamkhani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.2969 · Cited by 61
Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Dai, M., Yip, Y. Y., Hellström, I., & Hellström, K. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1339 · Cited by 60
Kim, Y. H., Choi, B. K., Kim, K. H., Kang, S. W., & Kwon, B. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1365 · Cited by 59
Korman, A. J., Chen, B., Wang, C., Wu, L., Cardarelli, P. M., & Selby, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.supp.48.37 · Cited by 47
Self-citationPhase I Study of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma (Mrcc)
Hammers, H. J., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Razak, A. R. A., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu342.3 · Cited by 46
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Kim, J. M., & Ashkenazi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131625 · Cited by 43
Anti–CTL-Associated Antigen 4: Are Regulatory T Cells a Target?
Gabriel, E. M., & Lattime, E. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2820 · Cited by 27
Frankel, T. L., Burns, W. R., Riley, J. P., Morgan, R. A., Davis, J. L., Hanada, K., Quezado, M., Rosenberg, S. A., & Royal, R. E. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0897-y · Cited by 26
Tirapu, I., Mazzolini, G. D., Rodrı́guez-Calvillo, M., Arina, A., Palencia, B., Gabari, I., & Melero, I. (2002) · PubMed · Cited by 22
Self-citationBetter Performance of CARs Deprived of the PD-1 Brake
Morales‐Kastresana, A., Labiano, S., Quetglas, J. I., & Melero, I. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2157 · Cited by 10
Self-citation
Cited by
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Self-citation
Metadata
- Authors
- Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-07-24
- Volume
- 15
- Issue
- 8
- Pages
- 457-472
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1580205301
- Cited by
- 637
- References
- 184
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.